![Marc Fournier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mr. Marc Fournier started his first company in 1995, providing translation and English teaching services to large advertising agencies and consulting companies.
After selling his firm to the Institut Français de Gestion in 1997, he was involved in the development of several Internet companies in Silicon Valley, such as the online travel website 12degrees.
He also contributed to the first rounds of financing of several technology companies, including Envivio (video over IP) and Claria (Internet advertisement).
Mr. Fournier has been active in venture capital since 2000.
He co-founded the incubator Kangaroo Village in 2000, and joined SGAM in 2002 to take over the venture capital activity, managing portfolio companies such as Attitude Studio, Ekinops, Karavel (acquired by Opodo), NetAsq, Sarenza and Si Automation (acquired by PDF Solution).
M Fournier is a graduate from Tufts University and Ecole Supérieure de Commerce de Paris (ESCP).
He teaches at ESCP.
Postes actifs de Marc Fournier
| Sociétés | Poste | Début |
|---|---|---|
Serena Capital SAS
 Serena Capital SAS Investment ManagersFinance Serena Capital is an active venture capital investment manager focused on the information & technology services, internet & software, big data and articial intelligence sectors. The firm invests in technology-driven French and European startups with high growth potential. They target early-stage companies and aim to invest between EUR 1 and 4 million, exceptionally up to EUR 8 million. | Fondateur | 01/07/2008 |
Anciens postes connus de Marc Fournier
| Sociétés | Poste | Fin |
|---|---|---|
Société Générale Asset Mgmt Alternative Invt (Private Equity)
 Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia. | Private Equity Investor | 01/09/2008 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
16
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Société Générale Asset Mgmt Alternative Invt (Private Equity)
Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia. | Finance |
Serena Capital SAS
Serena Capital SAS Investment ManagersFinance Serena Capital is an active venture capital investment manager focused on the information & technology services, internet & software, big data and articial intelligence sectors. The firm invests in technology-driven French and European startups with high growth potential. They target early-stage companies and aim to invest between EUR 1 and 4 million, exceptionally up to EUR 8 million. | Finance |
Choisissez Zonebourse 
